Table 1.

Characteristics of all patients included in the study analysis.

	COVID positive	COVID negative	Pre-COVID
All patients
n	20	31	37
T2DM, n	15/20	2/31	8/37
Median length of hospitalisation, days (IQR)	7.0 (5.2–19.5)	5 (1.9–8.2)	4.9 (2.3–11.4)
Median age, years (IQR)	59.8 (43.0–69.0)	50.9 (33.3–60.9)	31 (24.4–54.2)
Male gender, n	14/20	19/31	22/37
Median weight, kg (IQR)	76.2 (51.7–86.1)	65.4 (58.9–70.7)	63 (55.1–75.0)
Median height, m (IQR)	1.73 (1.7–1.8)	1.6 (1.6–1.7)	1.7 (1.6–1.8)
SGLT2 inhibitors, n	6/20	1/31	0/37
ACEi/ARB, n	6/20	1/31	1/37
ITU admission, n	6/20	4/31	0/37
Deaths, n	4/20	1/31	0/37
Episodes of hypokalaemia, n (IQR)	0 (0–0)	1 (0–4)	0 (0–0)
Episodes of hyperkalaemia, n (IQR)	0 (0–1)	0 (0–1)	0 (0–0)
T1DM
n	5	29	29
Median length of hospitalisation, days (IQR)	4.5 (4.3–4.8)	5 (1.9–8.0)	3.6 (2.1–7.8)
Median age, years (IQR)	30.9 (27.0–45.0)	47.4 (33.2–58.9)	26.5 (23.9–49.8)
Male gender, n	2/5	17/29	16/29
Median weight, kg (IQR)	67.9 (49.4–86.7)	65.7 (58.5–71.1)	60.7 (55.1–71.1)
Median height, m (IQR)	1.7 (1.7–1.8)	1.6 (1.6–1.7)	1.7 (1.6–1.7)
SGLT2 inhibitors, n	0/5	0/29	0/29
ACEi/ARB, n	0/5	1/29	0/29
ITU admission, n	2/5	4/29	0/29
Deaths, n	0/5	1/29	0/29
Episodes of hypokalaemia, n (IQR)	0 (0–2)	0.5 (0–3)	0 (0–0)
Episodes of hyperkalaemia, n (IQR)	1 (0–1)	0 (0–0.75)	0 (0–0)
T2DM
n	15	2	8
Median length of hospitalisation, days (IQR)	10.0 (6.0–20.0)	10.8 (7.4–14.2)	11.2 (8.1–18.7)
Median age, years (IQR)	63.0 (58.8–75.0)	72.7 (70.9–74.6)	58.0 (50.5–70.4)
Male gender, n	12/15	2/2	6/8
Median weight, kg (IQR)	76.2 (64.8–83.4)	60.0 (60.0–60.0)	98.0 (59.4–114.0)
Median height, m (IQR)	1.7 (1.7–1.7)	1.7 (1.7–1.7)	1.8 (1.7–1.8)
SGLT2 inhibitors, n	6/15	1/2	0/8
ACEi/ARB, n	6/15	0/2	1/8
ITU admission, n	4/15	0/2	1/8
Deaths, n	4/15	0/2	0/8
Episodes of hypokalaemia, n (IQR)	0 (0–0)	2.5 (1–4)	0 (0–0.75)
Episodes of hyperkalaemia, n (IQR)	0 (0–1)	0 (0–0)	0 (0–0)